Puma Biotechnology Reports Second Quarter 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Citi agrees to acquire rewards platform Kard Financial
- Total darkness, then sunset as full eclipse wows spectators in Spain
- Burry doubles down on Nebius short after stock surges 34% on earnings
Puma Biotech (PBYI) Tops Q2 EPS by 9c
August 9, 2018 4:14 PM EDTPuma Biotech (NASDAQ: PBYI) reported Q2 EPS of ($1.17), $0.09 better than the analyst estimate of ($1.26). Revenue for the quarter came in at $50.8 million versus the consensus estimate of $45.67 million.
For earnings history and earnings-related data on Puma Biotech (PBYI) click here.
... More